Virax Biolabs Group Ltd experienced a significant price increase of 40.48%, crossing above its 5-day SMA. This surge comes amid broader market weakness, with the Nasdaq-100 and S&P 500 both down 0.16%. The stock's resilience suggests sector rotation as investors shift focus to biotech companies.
The positive movement in Virax Biolabs' stock is attributed to sector rotation, as investors are increasingly interested in biotech amid a challenging market environment. This shift indicates a potential reallocation of capital towards companies that are perceived to have strong growth prospects in the current climate.
Investors may view this price movement as a signal of confidence in Virax Biolabs' future performance, especially as the biotech sector continues to attract attention. The company's ability to rise despite overall market declines could indicate a strong underlying demand for its products or services.
Wall Street analysts forecast VRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast VRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.290
Low
1.00
Averages
1.00
High
1.00
Current: 0.290
Low
1.00
Averages
1.00
High
1.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$3 -> $1
2026-01-09
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $1
AI Analysis
2026-01-09
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Virax Biolabs to $1 from $3 and keeps a Buy rating on the shares. Virax Biolabs outlined 2026 priorities focused on advancing ViraxImmune for Post-Acute Infection Syndromes, including reporting initial data from two fully enrolled U.K. studies in 2Q26 to support potential MHRA submission, launching a U.S. long COVID study with Emory University, and expanding ImmuneSelect RUO commercialization, the analyst tells investors in a research note. Recent mechanistic data show clear T-cell exhaustion and dysfunction in PAIS patients, consistent with the immune signatures ViraxImmune is designed to detect, with the company's current market value estimated at approximately $26M, the firm says.
HC Wainwright & Co.
Yi Chen
Strong Buy
Initiates
$3
2025-03-31
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-31
Initiates
Strong Buy
Reason
About VRAX
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
